Medicament For the Treatment of Central Nervous System Disorders
First Claim
Patent Images
1. The use of a molecule, alone or in combination, chosen from the group of molecules having a simultaneous antagonist action on the alpha1-noradrenergic, glutamatergic NMDA and serotoninergic 5HT2 receptors, for the preparation of a medicament intended for treating pathologies of the central nervous system.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to the use of a molecule, alone or in combination, chosen from the group of molecules having a simultaneous antagonist action on the alpha1-noradrenergic, glutamatergic NMDA and serotoninergic 5HT2 receptors, for the preparation of a medicament intended for treating pathologies of the central nervous system.
-
Citations
10 Claims
- 1. The use of a molecule, alone or in combination, chosen from the group of molecules having a simultaneous antagonist action on the alpha1-noradrenergic, glutamatergic NMDA and serotoninergic 5HT2 receptors, for the preparation of a medicament intended for treating pathologies of the central nervous system.
-
7. A pharmaceutical composition comprising at least two molecules chosen from the group of molecules having a simultaneous antagonist action on the alpha1-noradrenergic, glutamatergic NMDA and serotoninergic 5HT2 receptors consisting of the following molecules:
1-(1-naphthyl)piperazine, seganserin, olanzapine, sarprogelate, mirtazapine, aripiprazole, mepiprazole, 4-(4-fluorobenzoyl)-1-(4-phenylbutyl)piperidine, AMI-193, amperozide, cinanserin, clozapine, cyclobenzaprine, ketanserin, MDL 11,939, metergoline, methiothepin, methysergide, mianserin, N-desmethylclozapine, piperazine, pirenperone, ritanserin, RS 102221, sertindole, SB 200646, SB 204741, SDZ SER 082, spiperone, AH 11110, amosulalol, corynanthine, HEAT, naftopidil, niguldipine, bunazosin, dapiprazole, prazosin, tamsulosin, RS 100329, RS 17053, terazosin, WB 4101, urapidil, 5-methylurapidil, (−
)-MK801, (+)-MK801, (+/−
)-1-(1,2-diphenylethyl)piperidine, (2R, 3S)-Chlorpheg, (R)-4-carboxyphenyglycine, (R)-CPP, (RS)-CPP, arcaine, CGP 37849, CGP 39551, CGS 19755, D-AP5, D-AP7, DL-APS, DL-AP7, L-AP5, loperamide, LY 235959, memantine, SDZ 220-040, SDZ 220-581, synthalin, and their pharmacologically acceptable salts, combined with a pharmaceutically acceptable vehicle or excipient.- View Dependent Claims (8, 9, 10)
Specification